WuXi Biologics is trading at HK$50.05, down 4.94%, with the decline’s driver unclear.

  • No clear company-specific announcement or confirmed October 13 catalyst explaining the decline surfaced in available coverage.
  • The latest company news located was an October 9 conference update.
  • The recently reported FDA inspection pass was positive, not an evident explanation. Available evidence does not establish that broader market or sector conditions directly caused the move.